Good tolerability equals good results: the patient's perspective

被引:56
作者
Naber, D [1 ]
Karow, A [1 ]
机构
[1] Univ Hamburg, Hosp Psychiat & Psychotherapy, D-20247 Hamburg, Germany
关键词
antipsychotics; schizophrenia; side effects subjective effects; quality of life;
D O I
10.1016/S0924-977X(01)00110-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although conventional antipsychotics are useful for the treatment of schizophrenia, many patients discontinue taking them within a few months. As well as the positive influence of a good doctor-patient relationship, evidence suggests that the patient's initial subjective experience during antipsychotic therapy is a major predictor of compliance. In addition to motor symptoms, conventional antipsychotics can cause significant adverse effects on drive, emotion and cognition, which are reflected in patients complaining of a reduced quality of life, although may not be detected by objective examination. This syndrome, which is similar to the negative symptoms of schizophrenia, is known by numerous terms including 'pharmacogenic depression' and 'pharmacogenic anhedonia'. The introduction of atypical antipsychotics broadened the criteria for effective antipsychotic treatment to include the subjective assessment of improvement in patients' quality of life. The previous lack of interest in this domain may have been due to the inability to improve it with conventional agents and the misconception that schizophrenic patients were unable to subjectively evaluate their quality of life. However, numerous studies have shown that 63-95% of patients in remission are able to self-rate their affective state of well being or quality of life. Atypical antipsychotics are superior to conventional antipsychotics in improving quality of life and reducing the stigma of schizophrenia, particularly from the patient's perspective and are strong reasons for the widespread use of these drugs. (C) 2001 Elsevier Science BM All rights reserved.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 38 条
[1]   Patients subjective experiences on antipsychotic medications: Implications for outcome and quality of life [J].
Awad, AG ;
Hogan, TP ;
Voruganti, LNP ;
Heslegrave, RJ .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :123-132
[2]   SUBJECTIVE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA [J].
AWAD, AG .
SCHIZOPHRENIA BULLETIN, 1993, 19 (03) :609-618
[3]   DRUG-THERAPY IN SCHIZOPHRENIA - VARIABILITY OF OUTCOME AND PREDICTION OF RESPONSE [J].
AWAD, AG .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1989, 34 (07) :711-720
[4]  
BALDESSARINI RJ, 1980, AM J PSYCHIAT, V137, P753
[5]   DEPRESSIVE SYNDROMES IN SCHIZOPHRENIC-PATIENTS AFTER DISCHARGE FROM HOSPITAL [J].
BANDELOW, B ;
MULLER, P ;
GAEBEL, W ;
KOPCKE, W ;
LINDEN, M ;
MULLERSPAHN, F ;
PIETZCKER, A ;
REISCHIES, FM ;
TEGELER, J .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1990, 240 (02) :113-120
[6]   Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment [J].
Bobes, J ;
Gutierrez, M ;
Gibert, J ;
Gonzalez, MP ;
Herraiz, L ;
Fernandez, A .
EUROPEAN PSYCHIATRY, 1998, 13 (03) :158-163
[7]   A 2-YEAR PROSPECTIVE-STUDY OF TREATMENT COMPLIANCE IN PATIENTS WITH SCHIZOPHRENIA [J].
BUCHANAN, A .
PSYCHOLOGICAL MEDICINE, 1992, 22 (03) :787-797
[8]   The use of atypical antipsychotics in the management of schizophrenia [J].
Campbell, M ;
Young, PI ;
Bateman, DN ;
Smith, JM ;
Thomas, SHL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) :13-22
[9]   Neuroleptic-induced hyperprolactinemia [J].
Dickson, RA ;
Glazer, WM .
SCHIZOPHRENIA RESEARCH, 1999, 35 :S75-S86
[10]   NEUROLEPTIC DYSPHORIA [J].
EMERICH, DF ;
SANBERG, PR .
BIOLOGICAL PSYCHIATRY, 1991, 29 (03) :201-203